Nanoportal Biotech's EASY Technology-Powered Platform Honored Again at Prestigious ASH 2025 Meeting, Showcasing Breakthrough in Hematopoietic Stem Cell Gene Editing
The world's first non-viral gene delivery system earns consecutive recognition at the American Society of Hematology annual meeting, underscoring its potential to overcome key bottlenecks in gene therapy.
EASY technology has been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition for the second consecutive year. This reaffirms deep recognition from the world's premier hematology forum for this innovative technology in one of gene therapy's most challenging core areas.
The study to be presented, titled "A Mammalian Coacervate-Based Platform for High-Efficiency Gene Editing in Hematopoietic Stem Cells," highlights the platform's successful application in genetically modifying hematopoietic stem cells (HSCs). The clinical translation of gene therapies, especially for inherited blood disorders, has long been hindered by the industry-wide challenge of safely and efficiently editing HSCs. Conventional methods face limitations such as low efficiency (lipids), high cell damage (electroporation), or potential safety risks (viral vectors).
Overcoming the Core Challenge in Gene Therapy
Built on the proprietary EASY technology, ProteanFectTM provides a disruptive solution by mimicking endogenous cellular condensates. It self-assembles with nucleic acids to form nanoparticles, leveraging cells' active uptake mechanisms to achieve highly efficient, low-toxicity, and non-viral delivery of gene-editing tools into HSCs. The platform maintains high cell viability and functionality, showcasing its significant potential as a clinically translatable non-viral therapeutic platform to cure a range of diseases.
A Platform Validated by Global Peers
The superior performance of ProteanFectTM has garnered extensive international validation across multiple dimensions:
Top-Tier Publications: Research enabled by ProteanFectTM has been published in leading international journals including Nature Cell Biology, Nature Communications, Nature Genetics, Signal Transduction and Targeted Therapy.
Premier Conference Recognition: Beyond back-to-back selections at ASH, it was featured as a "Late-Breaking Abstract" at the 2025 International Society for Stem Cell Research (ISSCR) Annual Meeting and presented through oral and poster sessions at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
Global Commercialization: In November 2025, Nanoportal Biotech entered a strategic partnership with OriGene, marks a major breakthrough in entering the global market system.
Invitation to Connect at ASH 2025
The Nanoportal Biotech team will attend the ASH Annual Meeting in Orlando, Florida, from December 6-9, 2025. We invite global peers, partners, and media to connect at the conference to explore how our EASY technology-based platform addresses the longstanding industry challenges of poor transfection efficiency and high toxicity sensitivity in HSCs. Discover how this non-viral platform is reshaping the future of hematopoietic stem cell gene therapy.
